Genome-wide screening uncovers ACSL3's role in regulating lipotoxicity in MASLD, suggesting it as a therapeutic target.
ACSL3 is a central regulator of lipotoxic hepatocyte injury and MASLD progression, mechanistically linking lipid-droplet biogenesis to apoptosis and inflammatory niche formation. These data suggest that ACSL3 is a promising therapeutic target and support further translational studies to evaluate ACSL3 modulation in steatotic liver disease.
No takes yet. Share an insight, caveat, or question.
Myojin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: